E-drug: Boehringer-Ingelheim's and nevirapine (cont'd)
-------------------------------------------------------------------------
I would also suggest that it is a mistake to try to start such a
program using government public health facilities. I would advocate
that BI should aim to start their program in countries by involving
the private sector, employers who provide maternity care, and the
mission organizations. It would be much easier for these
organizations to scale up the distribution of Neverapine than it
would be for governments to offer such a program nation wide.
Richard Laing
Associate Professor of International Health
Boston University School of Public Health
715 Albany St, T4W, Boston MA 02118 USA
Tel 617 414-1444 Fax 617 638-4476
E-mail richardl@bu.edu
--
Send mail for the `E-Drug' conference to `e-drug@usa.healthnet.org'.
Information and archive http://www.healthnet.org/programs/edrug.html
Mail administrative requests to `majordomo@usa.healthnet.org'.
For additional assistance, send mail to: `owner-e-drug@usa.healthnet.org'.